Profile data is unavailable for this security.
About the company
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
- Revenue in AUD (TTM)0.00
- Net income in AUD-30.56m
- Incorporated2010
- Employees--
- LocationClarity Pharmaceuticals Ltd4 Cornwallis Street, National Innovation Centre,EVELEIGH 2015AustraliaAUS
- Phone+61 29209-4037
- Websitehttps://www.claritypharmaceuticals.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race Oncology Ltd | 885.59k | -11.17m | 260.39m | -- | -- | 12.52 | -- | 294.03 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
| Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 433.16m | 1.00 | -- | 9.37 | -- | 2,161.71 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
| Opthea Ltd | 174.98k | -241.49m | 444.08m | 5.00 | -- | -- | -- | 2,537.83 | -0.4629 | -0.4629 | 0.0003 | -0.1058 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
| PYC Therapeutics Ltd | 21.54m | -21.65m | 452.61m | 23.00 | -- | 12.11 | -- | 21.01 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
| Immutep Ltd | 256.62k | -40.50m | 517.14m | 19.00 | -- | 4.47 | -- | 2,015.21 | -0.0394 | -0.0394 | 0.0003 | 0.0973 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
| Imugene Ltd | 0.00 | -89.24m | 519.71m | 0.00 | -- | 2.61 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
| Mayne Pharma Group Ltd | 278.45m | -258.82m | 531.71m | 900.00 | -- | 0.927 | -- | 1.91 | -3.18 | -2.99 | 3.43 | 6.74 | 0.2105 | 0.8192 | 1.37 | -- | -19.56 | -14.47 | -26.66 | -18.05 | 68.05 | 50.60 | -92.95 | -64.69 | 1.30 | -5.68 | 0.0626 | -- | 20.75 | -18.54 | -51.49 | -- | 18.41 | -- |
| Clinuvel Pharmaceuticals Limited | 87.29m | 30.15m | 764.58m | 16.00 | 26.20 | 4.28 | 24.55 | 8.76 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
| Mesoblast Ltd | 11.16m | -109.17m | 1.17bn | 83.00 | -- | 1.37 | -- | 104.90 | -0.1323 | -0.1323 | 0.0136 | 0.7491 | 0.0112 | -- | 3.71 | 134,416.80 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -30.56m | 1.22bn | -- | -- | 19.48 | -- | -- | -0.1167 | -0.1167 | 0.00 | 0.2017 | 0.00 | -- | -- | -- | -41.34 | -- | -45.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.57 | -- | -- | -- |
| Polynovo Ltd | 84.68m | 1.59m | 1.52bn | 237.00 | 956.52 | 21.99 | 385.56 | 17.93 | 0.0023 | 0.0023 | 0.1207 | 0.10 | 0.9084 | 1.01 | 7.28 | 388,440.70 | 1.71 | -9.03 | 1.98 | -10.92 | 94.30 | 93.52 | 1.88 | -10.49 | 4.52 | -0.582 | 0.1817 | -- | 59.53 | 61.65 | -312.95 | -- | 47.35 | -- |
| Neuren Pharmaceuticals Ltd | 237.63m | 157.08m | 2.78bn | -- | 17.83 | 13.52 | 17.72 | 11.71 | 1.22 | 1.22 | 1.84 | 1.61 | 1.63 | -- | 21.92 | -- | 107.87 | 49.80 | 127.30 | 55.37 | -- | -- | 66.10 | 50.10 | -- | -- | 0.00 | 0.00 | 1,403.22 | 76.78 | 85,270.11 | 119.64 | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Argo Investments Ltd. (Investment Management)as of 20 Sep 2023 | 9.28m | 3.42% |
| Pengana Capital Ltd.as of 30 Nov 2023 | 2.62m | 0.97% |
| Investors Mutual Ltd.as of 30 Apr 2024 | 1.93m | 0.71% |
| Portland Investment Counsel, Inc.as of 30 Sep 2023 | 234.96k | 0.09% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 48.37k | 0.02% |
| DFA Australia Ltd.as of 31 Mar 2024 | 43.98k | 0.02% |
| PFM Asset Management LLCas of 31 Dec 2023 | 24.90k | 0.01% |
